Masayuki Furukawa

Masayuki Furukawa

Auto-generated profile, based on publicly available information

Masayuki Furukawa

Department of Hepato-Biliary-Pancreatology, National Hospital Organization, Kyushu Cancer Center, Fukuoka, Japan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2023 in Biological Trace Element Research
Verified
Journal Article
Open access
PDF file
RSRie Sugimoto
Rie Sugimoto
LLLingaku Lee
Lingaku Lee
YTYuki Tanaka
Yuki Tanaka
YMYusuke Morita
Yusuke Morita
MHMasayuki Hijioka
Masayuki Hijioka
MFMasayuki Furukawa
Masayuki Furukawa
Trace elements are minerals that are present in very low concentrations in the human body and yet are crucial for a wide range of physiological functions. Zinc, the second most abundant trace element, is obtained primarily from the diet. After being taken up in the intestine, zinc is distributed to various target organs, where it plays key roles in processes such as immunity, protein folding, apoptosis, and antioxidant activity. Given the important role of zinc in a wide range of enzymatic reactions and physiological processes, zinc deficiency has been identified in a variety of diseases, notably cancer. In recent years, multiple meta-analyses and reviews looking at zinc levels in individual cancer types have been published, as have a plethora of primary studies demonstrating a link between low zinc levels and specific types of cancer. In this review, we summarize recent evidence implicating low zinc concentrations in serum or tissues as a characteristic in a wide range of cancers. We also discuss preliminary findings indicating that zinc level measurement could ultimately become a useful clinical tool for cancer diagnosis and predicting outcomes in patients with cancer. Finally, we suggest future directions for further elucidating the role of zinc deficiency in cancer development and progression.

1 November 2025 in Journal of Clinical Oncology
Verified
Journal Article
Open access
AOAkihiro Ohba
Akihiro Ohba
MOMasato Ozaka
Masato Ozaka
JMJunki Mizusawa
Junki Mizusawa
Takuji OkusakaTakuji Okusaka
Takuji Okusaka
SKSatoshi Kobayashi
Satoshi Kobayashi
H(Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG)
Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG)
PURPOSE: Modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) and nab-paclitaxel + gemcitabine are recommended as first-line treatments for metastatic pancreatic cancer. S-1, irinotecan, and oxaliplatin (S-IROX) demonstrated activity in a phase Ib trial in this population. Therefore, these three regimens were directly compared. METHODS: This randomized phase II/III trial was performed at 45 centers in Japan. Eligible patients age 20-75 years with an Eastern Cooperative Oncology Group performance status of 0 or 1 and pathologically confirmed metastatic or recurrent pancreatic cancer were randomly assigned (1:1:1) to receive mFOLFIRINOX (oxaliplatin 85 mg/m 2 over 2 hours, irinotecan 150 mg/m 2 over 90 minutes, l-leucovorin 200 mg/m 2 over 2 hours, each once daily on day 1, and fluorouracil 2,400 mg/m 2 over 46 hours on days 1-3, every 2 weeks), S-IROX (oxaliplatin 85 mg/m 2 over 2 hours, irinotecan 150 mg/m 2 over 90 minutes on day 1, and S-1 80 mg/m 2 /day administered orally twice daily on days 1-7, every 2 weeks), or nab-paclitaxel (125 mg/m 2 ) + gemcitabine (1,000 mg/m 2 ) on days 1, 8, and 15 every 4 weeks. The primary end point was overall survival (OS). RESULTS: A total of 527 patients were enrolled, with 426 included in the planned interim analysis. The median OS was 14.0 months (hazard ratio [HR], 1.31 [95% CI, 0.97 to 1.77]) and 13.6 months (HR, 1.35 [95% CI, 1.00 to 1.82]) in the mFOLFIRINOX and S-IROX groups, respectively, as compared with 17.1 months in the nab-paclitaxel + gemcitabine group. The predictive probability of achieving superiority in the final analysis was <1% in both groups. Thus, the trial was terminated owing to its futility. Grade 3 to 4 anorexia was more frequent in the mFOLFIRINOX (23.3%) and S-IROX (27.5%) groups than in the nab-paclitaxel + gemcitabine group (5.0%). CONCLUSION: Neither mFOLFIRINOX nor S-IROX appeared to be superior compared with nab-paclitaxel + gemcitabine as the first-line treatment for metastatic or recurrent pancreatic cancer.

26 July 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
Junji FuruseJunji Furuse
Junji Furuse
MIMasafumi Ikeda
Masafumi Ikeda
MUMakoto Ueno
Makoto Ueno
MFMasayuki Furukawa
Masayuki Furukawa
CMChigusa Morizane
Chigusa Morizane
KYKouji Yamamoto
Kouji Yamamoto
Purpose: To evaluate the efficacy and safety of nanvuranlat [an L-type amino acid transporter 1 inhibitor] monotherapy as a later-line treatment in advanced, metastatic, and refractory biliary tract cancers. Patients and Methods: A multicenter, randomized, double-blind, placebo-controlled phase II study was conducted across fourteen leading Japanese cancer centers and hospitals. Nanvuranlat 25 mg/m2/day or placebo was given intravenously in cycles of 5 consecutive days, followed by 9 days off. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival and disease control rate. Subgroup analysis was performed in patients with high L-type amino acid transporter 1 expression and biliary tract cancer subtypes. Results: A total of 211 patients were screened, of which 105 eligible patients were randomized. Among these, 70 received nanvuranlat and 35 received placebo. Nanvuranlat demonstrated an improvement in PFS when compared with placebo (HR, 0.56; 95% confidence interval, 0.34–0.90; P = 0.02). Grade 3 or higher adverse events were reported in 30.0% and 22.9% of those in the nanvuranlat and placebo groups, respectively. The overall survival was not statistically different between nanvuranlat- and placebo-treated patients. An exploratory analysis indicated that nanvuranlat is warranted to evaluate its long-term clinical benefit in patients with intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer. Conclusions: Compared with placebo, nanvuranlat improved PFS in patients with advanced and refractory biliary tract cancer with an acceptable safety profile. Further studies of this promising compound are warranted in the population of patients who are exhausted from treatment options.

1 April 2025 in JCO Precision Oncology
Verified
Journal Article
Open access
KIKanae Inoue
Kanae Inoue
YNYoshiaki Nakamura
Yoshiaki Nakamura
BCBennett Caughey
Bennett Caughey
BZBinbin Zheng-Lin
Binbin Zheng-Lin
MUMakoto Ueno
Makoto Ueno
MIMasafumi Ikeda
Masafumi Ikeda
PURPOSE: This study aimed to investigate the clinicomolecular profiles and the efficacy of human epidermal growth factor receptor 2 (HER2)-targeted therapy in HER2 -amplified biliary tract cancer (BTC). METHODS: This study was an international collaboration that used combined data from the prospective SCRUM-Japan GOZILA and MONSTAR-SCREEN in Japan and retrospective reviews in the United States; patients with advanced BTC who had received systemic therapy were included. The clinicomolecular profiles were evaluated in an exploratory cohort, whereas the efficacy of HER2-targeted therapy was assessed in a biomarker-selected cohort. RESULTS: Of the 439 patients in the exploratory cohort, 43 (10%) had HER2 amplification. The frequencies of coalterations were higher in patients with HER2 amplification versus patients without HER2 amplification including HER2 mutations (26% v 5%, P < .001), TP53 mutations (84% v 61%, P = .003), and BRAF amplification (9% v 2%, P = .030). There were no KRAS mutations identified in patients with HER2- amplified BTC. No significant difference in overall survival (OS) was observed between patients with and without HER2 amplification (median, 17.7 v 16.9 months; hazard ratio [HR], 0.95 [95% CI, 0.65 to 1.40]). Of the 60 patients with HER2 -amplified BTC in the biomarker-selected cohort (43 from Japan and 17 from the United States), the OS was significantly longer in 29 patients who received HER2-targeted therapy than in those who did not receive HER2-targeted therapy (median, 24.3 v 12.1 months; HR, 0.39 [95% CI, 0.23 to 0.82]). Multivariate analysis identified HER2-targeted therapy as an independent prognostic factor for OS (HR, 0.29 [95% CI, 0.14 to 0.58]; P < .001). CONCLUSION: HER2 amplification was found in 10% of advanced BTC and was not identified as an independent prognostic factor for OS. Patients with HER2 -amplified BTC derive significant benefit from HER2-targeted therapy.

17 April 2024 in Future Oncology
Verified
Journal Article
Open access
YKYasuyuki Kawamoto
Yasuyuki Kawamoto
CMChigusa Morizane
Chigusa Morizane
YKYoshito Komatsu
Yoshito Komatsu
SKShunsuke Kondo
Shunsuke Kondo
MUMakoto Ueno
Makoto Ueno
TYTakayuki Yoshino
Takayuki Yoshino
Due to the widespread use of cancer genetic testing in gastrointestinal cancer, the BRCA1/2 genetic mutation has been identified in biliary tract cancer as well as pancreatic cancer. Niraparib is a... Plain language summary – A clinical study to confirm the efficacy and safety of niraparib for people with advanced biliary tract, pancreatic and other abdominal cancers with the BRCA genetic mutati...

1 March 2026 in JCO Precision Oncology
Verified
Journal Article
Open access
LLLingaku Lee
Lingaku Lee
YTYuichi Tachibana
Yuichi Tachibana
SMSusumu Matsuo
Susumu Matsuo
YNYusuke Niina
Yusuke Niina
TFTakashi Fujiyama
Takashi Fujiyama
MFMasayuki Furukawa
Masayuki Furukawa
PURPOSE: Germline BRCA (g BRCA ) mutations confer increased sensitivity to platinum-based chemotherapy and have been associated with improved survival across several malignancies. This study investigated the effect of g BRCA mutation status on the antitumor activity of modified fluorouracil, folinic acid, irinotecan, and oxaliplatin (FOLFIRINOX; mFFX) in patients with advanced pancreatic cancer (APC). METHODS: This multicenter retrospective study was performed in 178 patients with histologically confirmed APC who received mFFX, comprising 17 g BRCA -positive and 161 g BRCA -negative individuals. Efficacy outcomes, including progression-free survival (PFS), objective response rate (ORR), and normalization rate of carbohydrate antigen 19-9 (CA19-9), were compared between groups using univariate and multivariate analyses. RESULTS: Median PFS was significantly longer in g BRCA -positive than in g BRCA -negative patients (10.6 v 5.3 months, P = .005). Independent predictors of PFS included g BRCA mutation (hazard ratio [HR], 3.65), disease extent (HR, 2.34), and previous chemotherapy (HR, 1.66). g BRCA- positive patients demonstrated a significantly higher ORR (82% v 34%, odds ratio, 0.11, P < .001) and CA19-9 normalization rate (69% v 10%, P < 0.01). ORR was associated with g BRCA status (HR, 0.04), disease extent (HR, 0.11), and treatment history (HR, 0.27). Among 68 responders, sustained shrinkage of both primary and metastatic tumors and continued CA19-9 decline were observed during the first 6 months in g BRCA- positive patients, whereas responses in g BRCA -negative patients plateaued after 3 months. Subgroup analysis revealed that most patient subgroups demonstrated superior PFS and ORR in the g BRCA -positive cohort compared with those in the g BRCA -negative cohort. CONCLUSION: g BRCA mutation status was strongly associated with enhanced radiologic and biological responses to mFFX in APC. Routine screening for g BRCA mutations may provide essential guidance in therapeutic decision making and substantially improve clinical outcomes in this population.